TreatmentsVanda Pharmaceuticals Starts Phase III COVID-19 Trial of Tradipitant

Published 16 April 2020

Vanda Pharmaceuticals has partnered with The Feinstein Institutes for Medical Research’s arm Northwell Health to conduct a Phase III clinical trial of tradipitant to treat severe Covid-19 pneumonia. Clinical Trials Arena reports that enrolment for the trial, called ODYSSEY, has begun. The first patient was enrolled on 15 March at Lenox Hill Hospital, New York City. Tradipitant is a neurokinin-1 receptor (NK-1R) antagonist licensed by the company from Eli Lilly. The drug is being developed to treat gastroparesis, motion sickness, and atopic dermatitis. The double-blind, placebo-controlled, randomised ODYSSEY trial will assess the safety and efficacy of oral, 85mg twice-daily dose of the drug in treating neurogenic inflammation of the lung caused by Covid-19.